Davy James, Managing Editor

Treatment with bevacizumab and lomustine not found to offer a survival advantage.

Chemosensitivity, treatment variations, and socioeconomic factors may be a significant factor.

Engineered antibody treatment imitates functioning factor VIII to make blood clot properly.

Catch up with any news you missed this week on Specialty Pharmacy Times.

FDA decision expected in second half of 2016.

Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses why specialty pharmacies should seek accreditation.

Research finds patients are not staying on methotrexate long enough before switching to more costly biologic drugs.

Catch up with any news you missed last month.

Empliciti combination decreased disease progression risk by 30%.

Reolysin plus bortezomib and dexamethasone treats patients with relapsed or refractory multiple myeloma.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses developments affecting the specialty landscape.

Top articles from the leading specialty pharmacy journal.

Experimental personalized peptide cancer vaccine found to extend overall survival.

Therapeutic vaccine may reduce cervical cancer by fighting disease after infection.

Top stories of the week on Specialty Pharmacy Times.

Portrazza plus chemotherapy treats metastatic squamous non-small cell lung cancer in patients who were not previously treated specifically for advanced lung cancer.

Opdivo found to improve overall survival compared with other leading cancer therapies.

Tafinlar plus Mekinist found to improve overall survival in unresectable or metastatic BRAF-mutated melanoma.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses techniques specialty pharmacies can use to improve workflow and clinical activities in therapy management.

Concerns raised from combining medical marijuana dispensaries with recreational dispensaries.

Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide and dexamethasone.

Patients on Medicaid more likely to have HCV infection and much more likely to be denied coverage.

Top stories of the week on Specialty Pharmacy Times.

Specialty drugs for chronic, rare, and genetic diseases are forecast to drive a $298 billion increase in brand spending.

Treatment helps reduce infection risk from low white blood cell count in cancer patients receiving chemotherapy.

Novel drug shows promise in chronic lymphocytic leukemia and non-Hodgkin lymphoma refractory or resistant to current chemotherapies.

Atheer Kaddis, PharmD, senior vice president of Business Development and Sales at Diplomat, discusses retail network services.

FDA requests a more thorough review of rociletinib from ongoing trial.

Opdivo shows extended overall survival and fewer adverse events in patients with RCC compared with Afinitor.